v3.25.3
SCHEDULE OF AMOUNTS RECEIVABLE AND PREPAID EXPENSES (Details) - USD ($)
Jul. 31, 2025
Jul. 31, 2024
Receivables [Abstract]    
Directors and officers insurance $ 564,794 $ 632,657
Prepaid expense [1] 1,394,439 1,322,122
Subscription receipt [2] 736,359
Other prepaids 101,062 100,627
Amounts receivable and prepaid expenses 2,060,295 2,791,765
Prepaid expense non current $ 717,508 $ 1,211,946
[1] Prepaid expenses as of July 31, 2025 include amounts paid to certain vendors in respect of the Company’s ongoing pivotal phase III trial study. These amounts are amortized over the period of the clinical trial. Prepaid expenses estimated to be expensed within 12 months amount to $1,394,439 in 2025 compared to 1,322,122 in 2024 and are included in current assets, whilst the balance, extending longer than 12 months, amounts to $717,508 in 2025 as compared to 1,211,946 in 2024 and is included in non-current assets under long-term prepaid expenses.
[2] The subscription receipt relates to the May 2024 Offering (see note 9(b)(ii)(1)). All the funds have been received during the year ended July 31, 2025.